Jacobio Pharma receives breakthrough therapy designation for glecirasib

08 Aug 2023
www.pharmaceutical-technology.com
Breakthrough TherapyPriority ReviewClinical Result
Jacobio Pharma receives breakthrough therapy designation for glecirasib
Preview
Source: Pharmaceutical Technology
Glecirasib is intended for the treatment of pancreatic cancer patients with the KRAS G12C mutation. Credit: Nemes Laszlo/Shutterstock.com.
Jacobio Pharma has received breakthrough therapy designation (BTD) for glecirasib to treat pancreatic cancer patients with the KRAS G12C mutation.
The company’s in-house KRAS G12C inhibitorKRAS G12C inhibitor received the designation from the Center for Drug Evaluation of China’s National Medical Products Administration.
Recommended Reports
Jacobio Pharma receives breakthrough therapy designation for glecirasib
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Cyclosporin derivatives GlobalData
Jacobio Pharma receives breakthrough therapy designation for glecirasib
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Periodontitis drugs GlobalData
View all
The BTD has been granted based on the results from an ongoing pivotal, multi-centre, single-arm, open-label study that assessed the safety and efficacy of the single agent glecirasib.
Patients with KRAS G12C-mutated locally advanced or metastatic pancreatic cancer who progressed on frontline standard care treatment were enrolled in the trial.
In December 2022, glecirasib received the first BTD for treating advanced or metastatic non-small cell lung cancer (NSCLC) patients with the KRAS G12C mutation.
Jacobio is also currently conducting a pivotal Phase I/II monotherapy study in China evaluating glecirasib in STK11 [a germline mutation] co-mutated NSCLC patients in the front-line setting.
Combination therapy trials of glecirasib with SHP2 inhibitorSHP2 inhibitor JAB-3312 to treat NSCLC and with Cetuximab for colorectal cancer are also being carried out in the country.
Other Phase I/II clinical trials of glecirasib are ongoing in Europe and the US for treating patients with advanced solid tumours harbouring the KRAS G12C mutation.
The company also develops new molecules that target immune checkpoints, tumour metabolism and P53, RB and MYC-signalling pathways.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.